Induction of mucosal immunity against pathogens by using recombinant baculoviral vectors: Mechanisms, advantages, and limitations

J Leukoc Biol. 2020 Sep;108(3):835-850. doi: 10.1002/JLB.4MR0320-488R. Epub 2020 May 11.

Abstract

Over 90% of pathogens of medical importance invade the organism through mucosal surfaces, which makes it urgent to develop safe and effective mucosal vaccines and mucosal immunization protocols. Besides, parenteral immunization does not provide adequate protective immunity in mucosal surfaces. Effective mucosal vaccination could protect local and systemic compartments and favor herd immunity. Although various mucosal adjuvants and Ag-delivery systems have been developed, none has filled the gap to control diseases caused by complex mucosal pathogens. Among the strategies to counteract them, recombinant virions from the baculovirus Autographa californica multiple nucleopolyhedrovirus (rAcMNPV) are useful vectors, given their safety and efficacy to produce mucosal and systemic immunity in animal infection models. Here, we review the immunogenic properties of rAcMNPV virions from the perspectives of mucosal immunology and vaccinology. Some features, which are analyzed and extrapolated from studies with different particulate antigens, include size, shape, surface molecule organization, and danger signals, all needed to break the tolerogenic responses of the mucosal immune tissues. Also, we present a condensed discussion on the immunity provided by rAcMNPV virions against influenza virus and human papillomavirus in animal models. Through the text, we highlight the advantages and limitations of this experimental immunization platform.

Keywords: immunogenic features; mucosal immunization; mucosal pathogens; rAcMNPV virions; viral vector.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Alphapapillomavirus / immunology
  • Animals
  • Antigen Presentation
  • Antigens, Viral / administration & dosage
  • Antigens, Viral / genetics
  • Antigens, Viral / immunology
  • DNA, Viral / genetics
  • DNA, Viral / immunology
  • Dendritic Cells / immunology
  • Genetic Vectors / administration & dosage*
  • Genetic Vectors / genetics
  • Genetic Vectors / immunology
  • Humans
  • Immunity, Mucosal / immunology*
  • Influenza A Virus, H1N1 Subtype / immunology
  • Influenza Vaccines / immunology*
  • Mice
  • Nucleopolyhedroviruses / genetics
  • Nucleopolyhedroviruses / immunology*
  • Papillomavirus Vaccines / immunology*
  • Pathogen-Associated Molecular Pattern Molecules / immunology
  • Rats
  • Recombinant Proteins / genetics
  • Recombinant Proteins / immunology
  • Toll-Like Receptor 9 / immunology
  • Vaccination / methods*
  • Virion / immunology*

Substances

  • Antigens, Viral
  • DNA, Viral
  • Influenza Vaccines
  • Papillomavirus Vaccines
  • Pathogen-Associated Molecular Pattern Molecules
  • Recombinant Proteins
  • Toll-Like Receptor 9